Editorial: CAR T-Cell Therapies in Hematologic Tumors
Open Access
- 16 October 2020
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 588134
Abstract
Editorial: CAR T-Cell Therapies in Hematologic TumorsKeywords
This publication has 17 references indexed in Scilit:
- Therapeutic T cell engineeringNature, 2017
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with NeuroblastomaMolecular Therapy, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T LymphocytesJournal of Experimental Medicine, 1998
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regionsBiochemical and Biophysical Research Communications, 1987